UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

ONID APPROV	VAL
OMB Number:	3235-028
Estimated average but	rden
hours per response	0.

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person* CARUSO JAMES V				2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 06/05/2020							X Officer (give title below) Other (specify below) President and CEO					
(Street) FLORHAM, NJ 07932				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						es Acquire	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date, if r) any (Month/Day/Year)		te, if	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D) O	5. Amount of Securities B Owned Following Reporte Transaction(s) (Instr. 3 and 4)		ed	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
	(Month/Day/		r car)	Cod	le V	Amou	(A) or (D)	Price	iisu. 5 and 4)			or Indirect (I) (Instr. 4)				
Common	Stock		06/05/2020				P	2	21,74		\$ 1.145 44,2	4,264		I	D	
Reminder: I	Report on a se	eparate line for each	class of securities b	eneficial	ly own	ed direc	ctly o	Pers in th	ons wl is form	are not r	equired to	ollection of				1474 (9-02)
Reminder: I	Report on a so	eparate line for each		- Deriva	tive Se	curities	s Acq	Pers in th a cu uired, D	ons wlis form	are not ro valid OME of, or Bene	equired to 3 control ficially Ov	respond u number.				1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transac Code	tive Seats, cal	curities lls, war	s Acq rants er ative s s d (A) sed	Pers in th a cu uired, D	ons wlis form rrently sposed convertixersal	of, or Bene tible secur	equired to 3 control ficially Ow ities)	orespond unumber. wned and Amount rlying es	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form o Derivat Security Direct (or Indir (s) (I)	11. Natu of Indire Beneficity Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	- Derivat (e.g., pu 4. Transac Code	tive Seats, cal	Numb f Deriva ecurities curities curities curities f (D) fnstr. 3, nd 5)	s Acq rants er ative s s d (A) sed	Persin that a cultivated, Disconsisting of the Expiration	ons whis form rently sposed convertive exercisal on Date Day/Year	of, or Bene tible secur	ficially Owities) 7. Title a of Under Securitie	orespond unumber. wned and Amount rlying es	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Owners Form o Derivat Security Direct (or Indir	11. Natu of Indire Beneficity Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
CARUSO JAMES V C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM, NJ 07932	X		President and CEO		

Signatures

/s/ Christina Blakley, attorney-in-fact for James Caruso	06/08/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.